Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
El-Khoueiry, Anthony B, Sangro, Bruno, Yau, Thomas, Crocenzi, Todd S, Kudo, Masatoshi, Hsu, Chiun, Kim, Tae-You, Choo, Su-Pin, Trojan, Jörg, Welling, Theodore H, Meyer, Tim, Kang, Yoon-Koo, Yeo, WinniLangue:
english
Journal:
The Lancet
DOI:
10.1016/S0140-6736(17)31046-2
Date:
April, 2017
Fichier:
PDF, 833 KB
english, 2017
File converter
Plus de résultats de recherche
More benefits 
